Approach for innovation
Providing life-changing value to people, Kyowa Kirin keeps on taking on the challenge of building a platform for the creation of innovative new drugs by making full use of its proprietary antibody technologies and other diverse drug discovery technologies while utilizing the disease science we have cultivated to date.
Next Generation Therapeutic Antibodies
The distinguished fundamental technologies of Kyowa Kirin are characterized by POTELLIGENT® and human-antibody producing mice (human artificial chromosome vector) technologies which we successfully established, and contribute to efficient production of therapeutic antibodies.
Making the most of our knowledge and experience in protein and antibody engineering technology as well as in control of glycosylation, we are engaged in research and development of next generation therapeutic antibodies e.g., immune-activating antibodies and tissue-homing antibodies in collaboration with external research institutes.
New Type of Small Molecule Drugs
Our approach to small molecule drug discovery involves rational drug design, i.e., structure-based drug design (SBDD) ranging from the structural analysis of disease-associated biomolecules (therapeutic target) to the design of small molecules.
In pursuit of effective process from drug target hunting and seed discovery through producing drug candidates, we utilize phenotypic assay for disease state model, chemical biology, and bio- and chemo-informatics. In addition, we have initiated research in combining chemistry and biologics.
Nucleic Acid Drugs
Nucleic acid drug is seen with huge possibility in the future. In this area, we are working on developing technology for drug delivery systems, which is essential for nucleic acid drug, as well as technology for enhancing functions using nucleic acids. We are also actively engaged in collaborative research related to targets and new technologies with our partners.
Through these activities, we aim to create innovative new drugs especially for drug targets that are difficult to target with therapeutic antibodies or small molecule drugs.
Regenerative medicine is one of our research and development areas for establishing new technologies of drug discovery. We are engaged in exploring the novel and multiplex possibilities of cells based on our technologies and experience in genetic engineering and cell analysis.